References
- Andersen ME, Mckenna MJ. 1981. Saturable metabolism and its relationship to toxicity. Crit Rev Toxicol. 9(2):105–150.
- Apidra® – Scientific Discussion. 2005. https://www.ema.europa.eu/en/documents/scientific-discussion/apidra-epar-scientific-discussion_en.pdf.
- Baba T, Ryumin P, Duchoslav E, Chen K, Chelur A, Loyd B, Chernushevich I. 2021. Dissociation of biomolecules by an intense low-energy electron beam in a high sensitivity time-of-flight mass spectrometer. J Am Soc Mass Spectrom. 32(8):1964–1975.
- Bech EM, Pedersen SL, Jensen KJ. 2018. Chemical strategies for half-life extension of biopharmaceuticals: lipidation and its alternatives. ACS Med Chem Lett. 9(7):577–580.
- Bi M, Singh J. 1998. Degradation of luteinizing hormone releasing hormone in buccal, liver, nasal and skin tissues. Int J Pharm. 175(2):269–273.
- BioPharma FinderTM. 2022. https://www.thermofisher.com/order/catalog/product/OPTON-30416.
- Brodbelt JS, Morrison LJ, Santos I. 2020. Ultraviolet photodissociation mass spectrometry for analysis of biological molecules. Chem Rev. 120(7):3328–3380.
- Byetta® – Scientific Discussion. 2006. https://www.ema.europa.eu/en/documents/scientific-discussion/byetta-epar-scientific-discussion_en.pdf.
- Compound DiscovererTM. 2022. https://www.thermofisher.com/order/catalog/product/OPTON-31061?SID=srch-srp-OPTON-31061#/OPTON-31061?SID=srch-srp-OPTON-31061.
- Cuyckens F. 2019. Mass spectrometry in drug metabolism and pharmacokinetics: current trends and future perspectives. Rapid Commun Mass Spectrom. 33(S3):90–95.
- Cuyckens F, Dillen L, Cools W, Bockx M, Vereyken L, de Vries R, Mortishire-Smith RJ. 2012. Identifying metabolite ions of peptide drugs in the presence of an in vivo matrix background. Bioanalysis. 4(5):595–604.
- Datta-Mannan A. 2019. Mechanisms influencing the pharmacokinetics and disposition of monoclonal antibodies and peptides. Drug Metab Dispos. 47(10):1100–1110.
- de Veer SJ, Furio L, Harris JM, Hovnanian A. 2014a. Proteases: common culprits in human skin disorders. Trends Mol Med. 20(3):166–178.
- de Veer SJ, Furio L, Harris JM, Hovnanian A. 2014b. Proteases and proteomics: cutting to the core of human skin pathologies. Proteomics Clin Appl. 8(5-6):389–402.
- Deckert T, Hansen B, Lauritzen T, Christiansen JS. 1981. Subcutaneous degradation of insulin. Diabetologia. 21(2):161–162.
- Di L. 2015. Strategic approaches to optimizing peptide ADME properties. Aaps J. 17(1):134–143.
- Diao L, Meibohm B. 2013. Pharmacokinetics and pharmacokinetic–pharmacodynamic correlations of therapeutic peptides. Clin Pharmacokinet. 52(10):855–868.
- Ding Y, Ting JP, Liu J, Al-Azzam S, Pandya P, Afshar S. 2020. Impact of non-proteinogenic amino acids in the discovery and development of peptide therapeutics. Amino Acids. 52(9):1207–1226.
- Ellmerer M, Schaupp L, Brunner GA, Sendlhofer G, Wutte A, Wach P, Pieber TR. 2000. Measurement of interstitial albumin in human skeletal muscle and adipose tissue by open-flow microperfusion. Am J Physiol Endocrinol Metab. 278(2):E352–E356.
- Erckes V, Steuer C. 2022. A story of peptides, lipophilicity and chromatography – back and forth in time. RSC Med Chem. 13(6):676–687.
- Esposito S, de Leonibus ML, Ingenito R, Bianchi E, Orsatti L, Monteagudo E. 2018. A liquid chromatography high-resolution mass spectrometry in vitro assay to assess metabolism at the injection site of subcutaneously administered therapeutic peptides. J Pharm Biomed Anal. 159:449–458.
- Esposito S, Mele R, Ingenito R, Bianchi E, Bonelli F, Monteagudo E, Orsatti L. 2017. An efficient liquid chromatography-high resolution mass spectrometry approach for the optimization of the metabolic stability of therapeutic peptides. Anal Bioanal Chem. 409(10):2685–2696.
- Esposito S, Vanni D, Menta S, Orsatti L, Monteagudo E. 2020. Comparison of different protein precipitation and solid-phase extraction protocols for the study of the catabolism of peptide drugs by LC-HRMS. J Pept Sci. 26(9):e3272.
- Ewles M, Goodwin L. 2011. Bioanalytical approaches to analyzing peptides and proteins by LC–MS/MS. Bioanalysis. 3(12):1379–1397.
- Fatouros A, Lidén Y, Sjöström B. 2000. Recombinant factor VIII SQ–stability of VIII: C in homogenates from porcine, monkey and human subcutaneous tissue. J Pharm Pharmacol. 52(7):797–805.
- Fogh-Andersen N, Altura BM, Altura BT, Siggaard-Andersen O. 1995. Composition of interstitial fluid. Clin Chem. 41(10):1522–1525.
- Forteo® – Scientific Discussion. 2004. https://www.ema.europa.eu/en/documents/scientific-discussion/forsteo-epar-scientific-discussion_en.pdf.
- Gallo M, Vanni D, Esposito S, Alaimo N, Orvieto F, Rulli F, Missineo A, Caretti F, Bonelli F, Veneziano M, et al. 2022. Oligomerization, albumin binding and catabolism of therapeutic peptides in the subcutaneous compartment: an investigation on lipidated GLP-1 analogs. J Pharm Biomed Anal. 210 :114566.
- Ganesh AN, Heusser C, Garad S, Sánchez-Félix MV. 2021. Patient-centric design for peptide delivery: trends in routes of administration and advancement in drug delivery technologies. Med Drug Discov. 9:100079.
- Gradel AKJ, Porsgaard T, Lykkesfeldt J, Seested T, Gram-Nielsen S, Kristensen NR, Refsgaard HHF. 2018. Factors affecting the absorption of subcutaneously administered insulin: effect on variability. J Diabetes Res. 2018:1205121.
- Havelund S, Plum A, Ribel U, Jonassen I, Vølund A, Markussen J, Kurtzhals P. 2004. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res. 21(8):1498–1504.
- Henninot A, Collins JC, Nuss JM. 2018. The current state of peptide drug discovery: back to the future? J Med Chem. 61(4):1382–1414.
- Hijazi Y. 2021. Prediction of half-life extension of peptides via serum albumin binding: current challenges. Eur J Drug Metab Pharmacokinet. 46(2):163–172.
- Hövelmann U, Heise T, Nosek L, Sassenfeld B, Thomsen KMD, Haahr H. 2017. Pharmacokinetic properties of fast-acting insulin aspart administered in different subcutaneous injection regions. Clin Drug Investig. 7(5):503.
- Howard JW, Kay RG, Pleasance S, Creaser CS. 2012. UHPLC for the separation of proteins and peptides. Bioanalysis. 4(24):2971–2988.
- Huang M-Q, Lin ZJ, Weng N. 2013. Applications of high-resolution MS in bioanalysis. Bioanalysis. 5(10):1269–1276.
- Humalog® – Product Information. 2006. https://www.ema.europa.eu/en/documents/product-information/humalog-epar-product-information_en.pdf.
- Humulin R® – Highlights of Prescribing Information. 2019. https://pi.lilly.com/us/humulin-r-pi.pdf.
- Ibeanu N, Egbu R, Onyekuru L, Javaheri H, Khaw PT, Williams GR, Brocchini S, Awwad S. 2020. Injectables and depots to prolong drug action of proteins and peptides. Pharmaceutics. 12(10):999–42.
- Ibraheem D, Elaissari A, Fessi H. 2014. Administration strategies for proteins and peptides. Int J Pharm. 477(1-2):578–589.
- Isin EM, Elmore CS, Nilsson GN, Thompson RA, Weidolf L. 2012. Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies. Chem Res Toxicol. 25(3):532–542.
- Ito Y, Murano H, Hamasaki N, Fukushima K, Takada K. 2011. Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles. Int J Pharm. 407(1–2):126–131.
- Jensen L, Helleberg H, Roffel A, van Lier JJ, Bjørnsdottir I, Pedersen PJ, Rowe E, Derving Karsbøl J, Pedersen ML. 2017. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 104:31–41.
- Kagan L. 2014. Pharmacokinetic modeling of the subcutaneous absorption of therapeutic proteins. Drug Metab Dispos. 42(11):1890–1905.
- Katsila T, Siskos AP, Tamvakopoulos C. 2012. Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry. Mass Spectrom Rev. 31(1):110–133.
- Kim H, Park H, Lee SJ. 2017. Effective method for drug injection into subcutaneous tissue. Sci Rep. 7(1):9613.
- Kinnunen HM, Sharma V, Contreras-Rojas LR, Yu Y, Alleman C, Sreedhara A, Fischer S, Khawli L, Yohe ST, Bumbaca D, et al. 2015. A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components. J Control Release. 214:94–102.
- Klepach A, Tran H, Ahmad Mohammed F, ElSayed MEH. 2022. Characterization and impact of peptide physicochemical properties on oral and subcutaneous delivery. Adv Drug Deliv Rev. 186:114322.
- Korfmacher WA. 2010. Using mass spectrometry for drug metabolism studies. Boca Raton FL: CRC Press.
- Lai X, Tang J, ElSayed MEH. 2021. Recent advances in proteolytic stability for peptide, protein, and antibody drug discovery. Expert Opin Drug Discov. 16(12):1467–1482.
- Lantus® – Prescribing Information. 2007. https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021081s024lbl.pdf.
- Lantus® – Scientific Discussion. 2005. https://www.ema.europa.eu/en/documents/scientific-discussion/lantus-epar-scientific-discussion_en.pdf.
- Lau JL, Dunn MK. 2018. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 26(10):2700–2707.
- Lee VHL. 1990. Protease inhibitors and penetration enhancers as approaches to modify peptide absorption. J Control Release. 13(2-3):213–223.
- Levemir, INN-insulin detemir. 2004. https://www.ema.europa.eu/en/documents/scientific-discussion/levemir-epar-scientific-discussion_en.pdf.
- Li C, Chu S, Tan S, Yin X, Jiang Y, Dai X, Gong X, Fang X, Tian D. 2021a. Towards higher sensitivity of mass spectrometry: a perspective from the mass analyzers. Front Chem. 9(1148):813359.
- Li D, Chow PY, Lin TP, Cheow C, Li Z, Wacker MG. 2021b. Simulate SubQ: the methods and the media. J Pharm Sci. Oct 30:S0022-3549(21)00593-1.
- López-Otín C, Bond JS. 2008. Proteases: multifunctional enzymes in life and disease. J Biol Chem. 283(45):30433–30437.
- Lu P, Takai K, Weaver VM, Werb Z. 2011. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol. 3(12):a005058.
- Ma S, Chowdhury SK. 2013. Data acquisition and data mining techniques for metabolite identification using LC coupled to high-resolution MS. Bioanalysis. 5(10):1285–1297.
- Macias LA, Santos IC, Brodbelt JS. 2020. Ion activation methods for peptides and proteins. Anal Chem. 92(1):227–251.
- Mallart S, Ingenito R, Bianchi E, Bresciani A, Esposito S, Gallo M, Magotti P, Monteagudo E, Orsatti L, Roversi D, et al. 2021. Identification of potent and long-acting single-chain peptide mimetics of human Relaxin-2 for cardiovascular diseases. J Med Chem. 64(4):2139–2150.
- Malm-Erjefalt M. 2010. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos Biol Fate Chem. 38:1944–1953.
- Mass-MetaSiteTM. 2022. https://www.moldiscovery.com/software/massmetasite/.
- McDonald TA, Zepeda ML, Tomlinson MJ, Bee WH, Ivens IA. 2010. Subcutaneous administration of biotherapeutics: current experience in animal models. Curr Opin Mol Ther. 12(4):461–470.
- MEROPS – the Peptidase Database. 2022. https://www.ebi.ac.uk/merops/index.shtml.
- Metabolite PilotTM. 2022. https://sciex.com/tech-notes/pharma/discovery/metabolitepilot-software-2-0.
- Mitra MS, DeMarco S, Holub B, Thiruneelakantapillai L, Thackaberry EA. 2020. Development of peptide therapeutics: a nonclinical safety assessment perspective. Regul Toxicol Pharmacol. 117:104766.
- Mitragotri S, Burke PA, Langer R. 2014. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 13(9):655–672.
- Moore JE, Bertram CD. 2018. Lymphatic system flows. Annu Rev Fluid Mech. 50:459–482.
- Moriya Y, Kogame A, Tagawa Y, Morohashi A, Kondo T, Asahi S, Benet LZ. 2019. The enhancement of subcutaneous first-pass metabolism causes nonlinear pharmacokinetics of TAK-448 after a single subcutaneous administration to rats. Drug Metab Dispos. 47(9):1004–1012.
- Müller AC, Breitwieser FP, Fischer H, Schuster C, Brandt O, Colinge J, Superti-Furga G, Stingl G, Elbe-Bürger A, Bennett KL. 2012. A comparative proteomic study of human skin suction blister fluid from healthy individuals using immunodepletion and iTRAQ labeling. J Proteome Res. 11(7):3715–3727.
- Muttenthaler M, King GF, Adams DJ, Alewood PF. 2021. Trends in peptide drug discovery. Nat Rev Drug Discov. 20(4):309–325.
- Olsen J, Kofoed J, Ostergaard S, Wulff BS, Nielsen FS, Jorgensen R. 2016. Metabolism of peptide YY 3-36 in Göttingen mini-pig and rhesus monkey. Peptides. 78:59–67.
- Ono S, Egawa G, Kabashima K. 2017. Regulation of blood vascular permeability in the skin. Inflamm Regen. 37(1):1–8.
- Østergaard S, Paulsson JF, Kofoed J, Zosel F, Olsen J, Jeppesen CB, Spetzler J, Ynddal L, Schleiss LG, Christoffersen BØ, et al. 2021. The effect of fatty diacid acylation of human PYY3-36 on Y2 receptor potency and half-life in minipigs. Sci Rep. 11(1):1–15.
- Ozempic® – Product Information. 2018. https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf.
- Parson JA, Rafferty B, Stevenson RW, Zanelli JM. 1979. Evidence that protease inhibitors reduce the degradation of parathyroid hormone and calcitonin injected subcutaneously. Br J Pharmacol. 66(1):25–32.
- Periti P, Mazzei T, Mini E. 2002. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet. 41(7):485–504.
- Plum A, Jensen LB, Kristensen JB. 2013. In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis. J Pharm Sci. 102(8):2882–2888.
- Poola N, Due B, Wright D, Brooks LR, Zaman F. 2022. Pharmacokinetics and pharmacodynamics of repository corticotropin injection compared with synthetic ACTH 1-24 depot and methylprednisolone in healthy subjects. Clinical Pharm in Drug Dev. 11(4):502–515.
- Porter CJH, Charman SA. 2000. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci. 89(3):297–310.
- Radchenko T, Brink A, Siegrist Y, Kochansky C, Bateman A, Fontaine F, Morettoni L, Zamora I. 2017. Software-aided approach to investigate peptide structure and metabolic susceptibility of amide bonds in peptide drugs based on high resolution mass spectrometry. PLOS One. 12(11):e0186461.
- Radchenko T, Fontaine F, Morettoni L, Zamora I. 2019. Software-aided workflow for predicting protease-specific cleavage sites using physicochemical properties of the natural and unnatural amino acids in peptide-based drug discovery. Wallner B, editor. PLOS One. 14(1):e0199270.
- Radchenko T, Kochansky CJ, Cancilla M, Wrona MD, Mortishire-Smith RJ, Kirk J, Murray G, Fontaine F, Zamora I. 2020. Metabolite identification using an ion mobility enhanced data-independent acquisition strategy and automated data processing. Rapid Commun Mass Spectrom. 34(12):e8792.
- Reitsma S, Slaaf DW, Vink H, van Zandvoort MAMJ, Oude Egbrink MGA. 2007. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch. 454(3):345–359.
- Revestive® – Product Information. 2017. https://www.ema.europa.eu/en/documents/product-information/revestive-epar-product-information_en.pdf.
- Richter WF, Bhansali SG, Morris ME. 2012. Mechanistic determinants of biotherapeutics absorption following SC administration. Aaps J. 14(3):559–570.
- Richter WF, Jacobsen B. 2014. Subcutaneous absorption of biotherapeutics: knowns and unknowns. Drug Metab Dispos. 42(11):1881–1889.
- Riley RJ, McGinnity DF, Austin RP. 2005. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos. 33(9):1304–1311.
- Ruan Q, Comstock K. 2021. A new workflow for drug metabolite profiling by utilizing advanced tribrid mass spectrometry and data-processing techniques. J Am Soc Mass Spectrom. 32(8):2050–2061.
- Ryou HW, Lee JW, Yoon K. A, Park ES, Chi SC. 1997. Effect of protease inhibitors on degradation of recombinant human epidermal growth factor in skin tissue. Arch Pharm Res. 20(1):34–38.
- Samant PP, Prausnitz MR. 2018. Mechanisms of sampling interstitial fluid from skin using a microneedle patch. Proc Natl Acad Sci Usa. 115(18):4583–4588.
- Sandostatin® – Prescribing Information. 2010. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019667s058,021008s023lbl.pdf.
- Saurina J, Sentellas S. 2019. Liquid chromatography coupled to mass spectrometry for metabolite profiling in the field of drug discovery. Expert Opin Drug Discov. 14(5):469–483.
- Schadt S, Hauri S, Lopes F, Edelmann MR, Staack RF, Villaseñor R, Kettenberger H, Roth AB, Schuler F, Richter WF, et al. 2019. Are biotransformation studies of therapeutic proteins needed? Scientific considerations and technical challenges. Drug Metab Dispos. 47(12):1443–1456.
- Sequeira JAD, Santos AC, Serra J, Estevens C, Seiça R, Veiga F, Ribeiro AJ. 2019. Subcutaneous delivery of biotherapeutics: challenges at the injection site. Expert Opin Drug Deliv. 16(2):143–151.
- Sohlenius-Sternbeck AK, Afzelius L, Prusis P, Neelissen J, Hoogstraate J, Johansson J, Floby E, Bengtsson A, Gissberg O, Sternbeck J, et al. 2010. Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds. Xenobiotica. 40(9):637–649.
- Sonesson A, Bjørnsdottir I, Christensen JK. 2021. Meeting report: 3rd workshop of the peptide ADME discussion group. Xenobiotica. 51(12):1470–1474.
- Srivastava V, editor. 2017. Peptide-based drug discovery. Cambridge: Royal Society of Chemistry.
- Stringer R, Nicklin PL, Houston JB. 2008. Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance. Xenobiotica. 38(10):1313–1329.
- Supersaxo A, Hein WR, Steffen H. 1990. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res. 7(2):167–169.
- Takeyama M, Ishida T, Kokubu N, Komada F, Iwakawa S, Okumura K, Hori R. 1991. Enhanced bioavailability of subcutaneously injected insulin by pretreatment with ointment containing protease inhibitors. Pharm Res. 8(1):60–64.
- Tibbitts J, Canter D, Graff R, Smith A, Khawli LA. 2016. Key factors influencing ADME properties of therapeutic proteins: a need for ADME characterization in drug discovery and development. Mabs. 8(2):229–245.
- Tokuda JM, Xie J, Jawa V, Hawkins JM, Ferbas J, Joh NH, Joubert MK. 2022. Use of in vitro human Skin models to assess potential immune activation in response to biotherapeutic attributes and process-related impurities. J Pharm Sci. 111(4):1012–1023.
- Tong W, Chowdhury S, Wrona M, Bateman K. 2012. Coupling of UHPLC with fast fraction collection-microplate scintillation counting and MS for radiolabeled metabolite profiling. Bioanalysis. 4(11):1299–1309.
- Torres-Terán I, Venczel M, Klein S. 2021. Prediction of subcutaneous drug absorption – do we have reliable data to design a simulated interstitial fluid? Int J Pharm. 610:121257.
- Tresiba® – Product Information. 2017. https://www.ema.europa.eu/en/documents/product-information/tresiba-epar-product-information_en.pdf.
- Usach I, Martinez R, Festini T, Peris JE. 2019. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 36(11):2986–2996.
- van der Vusse GJ. 2009. Albumin as fatty acid transporter. Drug Metab Pharmacokinet. 24(4):300–307.
- van Witteloostuijn SB, Pedersen SL, Jensen KJ. 2016. Half-life extension of biopharmaceuticals using chemical methods: alternatives to PEGylation. ChemMedChem. 11(22):2474–2495.
- Varkhede N, Bommana R, Schöneich C, Forrest ML. 2020. Proteolysis and oxidation of therapeutic proteins after intradermal or subcutaneous administration. J Pharm Sci. 109(1):191–205.
- Victoza® – Product Information. 2014. https://www.ema.europa.eu/en/documents/product-information/victoza-epar-product-information_en.pdf.
- Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, Wang X, Wang R, Fu C. 2022. Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther 2022;7(1):1–27.
- Wang M, Defranco D, Wright K, Quazi S, Chen J, Spencer-Pierce J, Zaghloul I, Pak R, Darvair R, Krishnan A. 2012a. Decreased subcutaneous bioavailability of an oxyntomodulin analog in a controlled release formulation could be caused by skin metabolism in rats. J Bioequiv Availab. 4(5):0–0.
- Wang W, Chen N, Shen X, Cunningham P, Fauty S, Michel K, Wang B, Hong X, Adreani C, Nunes CN, et al. 2012b. Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs. Drug Metab Dispos. 40(5):952–962.
- Wang Y, Lomakin A, Kanai S, Alex R, Belli S, Donzelli M, Benedek GB. 2016. The molecular basis for the prolonged blood circulation of lipidated incretin peptides: peptide oligomerization or binding to serum albumin? J Control Release. 241:25–33.
- Wen B, Zhu M. 2015. Applications of mass spectrometry in drug metabolism: 50 years of progress. Drug Metab Rev. 47(1):71–87.
- Werle M, Bernkop-Schnürch A. 2006. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 30(4):351–367.
- Wilkinson SD, Martin S, Orton AL, Markandu R, Jones BC. 2020. Drug metabolite identification using ultrahigh-performance liquid chromatography–ultraviolet spectroscopy and parallelized scans on a tribrid orbitrap mass spectrometer. Rapid Commun Mass Spectrom. 34(10):e8735.
- Yao J-F, Yang H, Zhao Y-Z, Xue M. 2018. Metabolism of peptide drugs and strategies to improve their metabolic stability. Curr Drug Metab. 19(11):892–901.
- Yao M, Cai T, Duchoslav E, Ma L, Guo X, Zhu M. 2020. Software-aided detection and structural characterization of cyclic peptide metabolites in biological matrix by high-resolution mass spectrometry. J Pharm Anal. 10(3):240–246.
- Yu X, Fridman A, Bagchi A, Xu S, Kwasnjuk KA, Lu P, Cancilla MT. 2020. Metabolite identification of therapeutic peptides and proteins by top-down differential mass spectrometry and metabolite database matching. Anal Chem. 92(12):8298–8305.
- Zhang D, Luo G, Ding X, Lu C. 2012. Preclinical experimental models of drug metabolism and disposition in drug discovery and development. Acta Pharm Sin B. 2(6):549–561.
- Zhu M, Zhang H, Humphreys WG. 2011. Drug metabolite profiling and identification by high-resolution mass spectrometry. J Biol Chem. 286(29):25419–25425.
- Zhu X, Chen Y, Subramanian R. 2014. Comparison of information-dependent acquisition, SWATH, and MS All techniques in metabolite identification study employing ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry. Anal Chem. 86(2):1202–1209.
- Zoladex – Summary of Product Characteristics. 2019. https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA1019-027-001_20062019122218.pdf.
- Zorzi A, Middendorp SJ, Wilbs J, Deyle K, Heinis C. 2017. Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides. Nat Commun. 8(1):16092–16099.